Tawasul
Mubasher TV
Contact Us Advertising   العربية

Pfizer begins study for novel COVID-19 oral antiviral drug

Pfizer begins study for novel COVID-19 oral antiviral drug

UAE - Mubasher: Pfizer has started a mid-to-late-stage study to evaluate the investigational novel oral antiviral drug for the prevention of coronavirus (COVID-19) infection as part of a global clinical research programme.

Co-administered with a low dose of ritonavir, the second phase trial is enrolling 2,660 healthy adult participants who are at least 18 years and live with a confirmed symptomatic COVID-19 infection, according to a press release on Monday.

The clinical trial aims to assess safety and efficacy for the prevention of confirmed COVID-19 infection and its symptoms through Day 14.

The MD, PhD., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer, Mikael Dolsten, said: "If successful, we believe this therapy could help stop the virus early – before it has had a chance to replicate extensively – potentially preventing symptomatic disease in those who have been exposed and inhibiting the onset of infection in others."